Transition plan in place
QUEBEC CITY, Oct. 1,
2013 /PRNewswire/ - DiagnoCure Inc. (TSX: CUR) (OTCQX:
DGCRF) (the "Corporation") announced today that Ms. Chantal Miklosi has resigned her position as
Chief Financial Officer of the Corporation effective October 11th. She will leave to pursue
other career opportunities. Dr. Yves
Fradet, President and Chief Medical Officer, supported by
Mr. Richard Bordeleau, Senior
Advisor, will maintain contact with investors and the general
public. Mr. Frédéric Boivin, Senior Director, who has served in
finances and administration for 12 years, will oversee financial
matters. Ms. Danielle Allard, Senior
Director, Corporate Affairs will continue to be responsible for all
filings to regulatory agencies.
Dr. Yves Fradet,
President and Chief Medical Officer said, "I want to thank Chantal
for her important contributions to the Corporation during her
tenure as Chief Financial Officer. She played an instrumental role
in negotiating and closing all of DiagnoCure's recent business
arrangements. We wish Chantal well in her new endeavors. As
communicated recently, the DiagnoCure team will continue working on
short-term initiatives aimed at increasing shareholder value and
exploring all opportunities to enhance longer-term prospects for
the Corporation."
About DiagnoCure
DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life
sciences corporation that develops and commercializes high-value
cancer diagnostic tests that increase clinician and patient
confidence in making critical treatment decisions. In 2008, the
Corporation launched a colorectal cancer staging test through its
U.S. CLIA laboratory. PrevistageTM GCC is currently
available for licensing. The Corporation has granted a worldwide
exclusive license on the diagnostic applications of its proprietary
molecular biomarker PCA3 to Gen-Probe, now a wholly-owned
subsidiary of Hologic Inc. Hologic Gen-Probe's PROGENSA® PCA3
prostate cancer test is commercialized in Europe under CE mark and is approved for
commercialization in Canada and
the United States. For more
information, please visit www.diagnocure.com.
Forward‐looking statements
This release may contain forward‐looking
statements that involve known and unknown risks, uncertainties and
assumptions that may cause actual results to differ materially from
those expected. Forward-looking statements can be identified by the
use of the conditional or forward-looking terminology such as
"anticipates", "assumes", "believes", "estimates", "expects",
"intend", "may", "plans", "projects", "should", "will", or the
negative thereof or other variations thereon. Forward-looking
statements also include any other statements that do not refer to
historical facts. All such forward-looking statements are made
pursuant to the "safe-harbour" provisions of applicable Canadian
securities laws. By their very nature, forward‐looking statements
are based on expectations and hypotheses and also involve risks and
uncertainties, known and unknown, many of which are beyond
DiagnoCure's control. Forward-looking statements are presented for
the purpose of assisting investors and others in understanding
certain key elements of the Corporation's current objectives,
strategic priorities, expectations and plans, and in obtaining a
better understanding of the Corporation's business and anticipated
operating environment. Readers are cautioned that such information
may not be appropriate for other purposes and that they should not
place undue reliance on these forward‐looking statements. For
instance, any forward-looking statements regarding the outcome of
research and development projects, clinical studies and future
revenues, including those related to PROGENSA® PCA3, are based on
management expectations and such outcome may vary materially
depending on global political and economic conditions, dependence
on collaboration partners, uncertainty of healthcare reimbursement,
and marketing and distribution challenges. In addition, the reader
is referred to the applicable general risks and uncertainties
described in DiagnoCure's most recent Annual Information Form under
the heading "Risk Factors". DiagnoCure undertakes no obligation to
publicly update or revise any forward‐looking statements contained
herein unless required by the applicable securities laws and
regulations.
SOURCE DiagnoCure inc.
